NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) resulting from allegations that ImmunityBio, Inc. may have issued materially misleading business information to the investing public. So What: If you purchased ImmunityBio, Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc. ...

In this article, we will look at the 10 Best Strong Buy Stocks to Invest In Under $20.On March 23, Dan Niles, founder and portfolio manager at Niles Investment Management, appeared on CNBC’s ‘Squawk on the Street’ to talk about market themes and the war in Iran. President Trump recently announced productive talks with Iran on the Iran war, with positive steps when it comes to negotiations and the potential end of the conflict. Niles was of the view that in these circumstances, one has to look at what the ri ...

ImmunityBio stock price crash: buy the dip or sell the rip? ImmunityBio stock price crash: buy the dip or sell the rip? Stock market Author Wajeeh Khan Mar 24, 2026, 19:25 PM ImmunityBio Inc (NASDAQ: IBRX) is under immense pressure on March 24 after the US Food and Drug Administration (FDA) issued a scathing warning letter over the firm's promotional tactics. Investors bailed on IBRX as regulators alleged the company and its billionaire founder, Dr. Patrick Soon- Shiong, used a TV ad and a high-profile podc ...

Key Takeaways ImmunityBio shares rose 11% after China approved Anktiva combo for bladder cancer treatment.Approval in China covers BCG-unresponsive NMIBC with CIS with or without papillary tumors.Anktiva plus BCG combo showed 71% complete response rate in the QUILT-3.032 study.Shares of ImmunityBio (IBRX) were up 11% on Monday after the company announced that Macau’s regulatory body has approved its lead drug, Anktiva, for treating certain patients with a type of bladder cancer.The regulatory body has appro ...

Just one day after its stock soared in response to Macau's approval of its oncology drug Anktiva® as a treatment for certain types of bladder cancer, as of 12:32 p.m. ET today, ImmunityBio (NASDAQ: IBRX) shares are down 22.4%. The prompt? A warning letter from the U.S. Food & Drug Administration indicating that a television ad promoting Anktiva -- as well as comments made by the company's Global Chief Scientific and Medical Officer and Executive Chairman Dr. Patrick Soon-Shiong during a recent podcast -- ...

San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ImmunityBio, Inc. (NASDAQ: IBRX). The investigation focuses on ImmunityBio executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased ImmunityBio securities?If you purchased ImmunityBio securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.Or for more i ...

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading lower after the FDA issued a warning to the company over misleading Anktiva promotions.ImmunityBio stock is feeling bearish pressure. What’s pressuring IBRX stock?FDA Flags Misleading Promotional ClaimsThe U.S. Food and Drug Administration determined that a direct-to-consumer TV ad and podcast promoting Anktiva were false or misleading and misbranded the drug under federal law. The FDA said the materials made unsupported claims that Anktiva could cure or pr ...

ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The corporate logo of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, 2009. REUTERS/Jason Reed/File Photo Purchase Licensing Rights, opens new tab Companies ImmunityBio did not immediately respond to a Reuters request for comment. Immunitybio Inc Follow U.S. Foo ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Ten stocks kicked off the trading week delivering strong gains, mimicking a broader market optimism after the US announced a five-day halt in strikes on Iran.Wall Street’s major indices all clocked in more than 1 percent gains, with the Nasdaq and the Dow Jones both leading the gains, up 1.38 percent. The S&P 500 also increased by 1.15 percent.In this article, we focus on the 10 top performers on Monday and detail the reasons behind their gains.To come up with the list, we focused on the stocks with a $2 bi ...